Phase III Fail Forces Neuphoria Into Strategic Review—With One Investor Offering a Takeover

Aside from offering to acquire all remaining shares of Neuphoria, existing investor Lynx1 Master Fund also announced its plan to nominate directors in the biotech’s upcoming board elections.

Scroll to Top